# Zuranolone as a Novel Therapy for Postpartum Depression: A Narrative Review of Current Evidence and Future Directions

## TL;DR

Zuranolone is a new oral treatment for postpartum depression that may offer faster and more effective relief compared to current options.

## Contribution

This paper reviews the emerging evidence for zuranolone as a novel therapy for postpartum depression and identifies key research and clinical priorities.

## Key findings

- Zuranolone shows promise as a novel oral therapy for postpartum depression with potential for rapid onset of action.
- Current evidence suggests zuranolone may have favorable tolerability compared to existing treatments.
- Key uncertainties remain regarding the duration of effect and long-term outcomes of zuranolone.

## Abstract

Postpartum depression (PPD) is a debilitating complication of childbirth and is associated with significant consequences for maternal well-being and infant development. Current pharmacological treatments have many limitations, including a delayed onset of action, variable response rates, and concerns about tolerability, underscoring the need for novel therapeutic approaches. Zuranolone has recently emerged as a novel oral therapy specifically for the treatment of PPD and represents a potential turning point in the management of PPD. This narrative review outlines the evolving evidence base for zuranolone, including current understanding of its efficacy and tolerability, and explores practical considerations for its use. The potential role of zuranolone within the broader treatment landscape is discussed, alongside key uncertainties regarding duration of effect, longer-term outcomes and accessibility. By synthesising available literature and identifying key knowledge gaps, this review aims to clarify the evolving role of zuranolone in the treatment of PPD, while highlighting priorities for future research and clinical practice.